H.C. Wainwright lowered the firm’s price target on Bionano Genomics (BNGO) to $7 from $11 and keeps a Buy rating on the shares. The firm adjusted the company’s model post the Q3 report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO: